Showing results (1541-1550 of 1,955) with videos related to

Sort By:
Pageof 196
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 26, 2017
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registryChiara Melloni, Peter Shrader, Joseph Carver, et al.
The Journal of Clinical Psychiatry|June 27, 2015
Interactions of borderline personality disorder and anxiety disorders over 10 yearsAlex S Keuroghlian, John G Gunderson, Maria E Pagano, et al.
British Journal of Cancer|March 20, 2018
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trialMichael L Maitland, Sarina Piha-Paul, Gerald Falchook, et al.
Mayo Clinic Proceedings|February 9, 2007
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinionMaria I Aguilar, Robert G Hart, Carlos S Kase, et al.
British Journal of Haematology|June 28, 2017
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapyUmar Farooq, Matthew J Maurer, Carrie A Thompson, et al.
Haematologica|June 16, 2018
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangementsEllen D McPhail, Matthew J Maurer, William R Macon, et al.
Blood Advances|November 29, 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapyDaniel M Witt, Robby Nieuwlaat, Nathan P Clark, et al.
Eclinicalmedicine|June 13, 2025
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus studySarah E Hughes, Foram Khatsuria, Christel McMullan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
Pageof 196